Clinical · Molecular biology
Meningioma methylation profiling as a complement to WHO grading: a single-center experience
This retrospective study assessed the clinical relevance of methylation profiling for meningioma risk stratification in 106 patients. Results indicated that methylation profiling, performed using the MethylationEPIC v1.0 chip, was a significantly superior predictor of tumor progression (r = -0.4, p < 0.001) compared to WHO 2021 grading. Although methylation profiling demonstrated enhanced predictive accuracy, particularly for identifying malignant meningiomas, its immediate clinical utility is constrained by a high rate of unclassified tumors (29%) and a delayed turnaround time for results (median 23 days), which is incompatible with prompt postoperative decision-making. The authors conclude that methylation profiling serves as a valuable complementary tool but cannot currently replace established histopathological assessment.